A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.

NCT07140614 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Charcot-Marie-Tooth Disease, Type 1A

Interventions

DRUG: EDK060, dose A
DRUG: EDK060, dose B
DRUG: EDK060, dose C
DRUG: EDK060, dose D
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals